CD274 and thymic carcinoma: Recent studies on immunotherapeutic target molecules in thymic carcinoma have shown frequent expression of programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1) in thymic carcinoma and an association of PD-L1 expression with improved survival.